BRSYF Brainsway Ltd.

NEUTRAL Impact: 4/10 6-K
Horizon weeks Filed May 18, 2026 Processed 22d 18h ago SEC 0001171843-26-003501
Notable filing: 6-K
Latest settled — T+5d
BRSYF ▲ 0.00% at T+5d
NEUTRAL call ✗ call lost 0.00% · α vs SPY -1.62% · entry $16.84 → $16.84
Next anchor: T+20d in 6d
Last close $16.84 (close Jun 8) · +0.00% from $16.84 entry
Entry anchored
May 18, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.65%
$16.84
settled 22d ago
T+5d
0.00%
call 0.00% · α -1.62%
$16.84
settled 15d ago
T+20d
call — · α —
in 6d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

BrainsWay announced a minority-stake investment of $1.5 million (with potential for an additional $1.5 million via milestones) in Hopemark Health, a mental health provider in Illinois. This is a continuation of BrainsWay's strategy to partner with clinical platforms to expand access to its Deep TMS technology. The investment is small relative to BrainsWay's $52.2 million annual revenue and is not expected to materially impact near-term financials.

Actionable Insight

This is a routine strategic investment with no immediate earnings impact. Monitor for future milestone payments and any revenue contribution from Hopemark, but the near-term stock catalyst is minimal. The prior 20-F showed strong fundamentals, and this deal does not alter that trajectory.

Key Facts

  • BrainsWay will invest $1.5 million initially, with potential for an additional $1.5 million via milestone-based investments, for a minority position in Hopemark Health.
  • The investment is in the form of a preferred, annually compounding security with a redemption mechanism.
  • This is part of a series of similar minority-stake investments by BrainsWay in North American mental health providers.
  • BrainsWay reported 2025 revenue of $52.2 million and net income of $7.6 million in its recent 20-F filing.
  • The transaction is small-scale (up to $3 million total) and does not change BrainsWay's core business or financial outlook.

Financial Impact

Up to $3 million total investment, representing approximately 5.7% of BrainsWay's 2025 annual revenue of $52.2 million. The initial $1.5 million is about 2.9% of revenue.

cashinvestment securities

Risk Factors

  • Investment may not produce profitable returns, as noted in the forward-looking statement risk factors.
  • Milestone-based additional investment may not materialize if Hopemark underperforms.
  • Minority stake provides limited control over Hopemark's operations.

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-003501
Document: f6k_051726.htm0001171843-26-003501
Document: 0001171843-26-003501-index-headers.html0001171843-26-003501
Document: 0001171843-26-003501-index.html0001171843-26-003501
Document: 0001171843-26-003501.txt0001171843-26-003501
5 reports for BRSYF
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+20▲ +24.28%Apr 15, 2026
Filters
Rows
Reports for BRSYF — sortable, filterable
Type Now
Jun 9, 2026
today
6-K
BULLISH ★ 7/10
awaiting T+5
May 18, 2026
22d ago
6-K
NEUTRAL ★ 4/10
$16.84 $16.84· 0.00%▼ −1.62%$16.84 (+0.00%)
May 13, 2026
27d ago
6-K
BULLISH ★ 8/10
$16.84 $16.84· 0.00%▲ +1.16%$16.84 (+0.00%)
Apr 20, 2026
7w ago
20-F
BULLISH ★ 7/10
$13.55 $13.55· 0.00%▼ −1.08%$16.84 (+24.28%)
Apr 15, 2026
7w ago
6-K
BULLISH ★ 7/10
$13.55 $13.55· 0.00%▼ −1.64%$16.84 (+24.28%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 6h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access